Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 04, 2024 09:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 04, 2024 09:00 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development...
Adoptive Cell Therapy Clinical Trials Report, 2024: Trends, Key Segments, Top Sponsors, and Virtual Components
October 02, 2024 09:29 ET
|
Research and Markets
Dublin, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Adoptive Cell Therapy" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of Adoptive...
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 09:05 ET
|
Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
September 27, 2024 14:00 ET
|
Neurona Therapeutics
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
September 26, 2024 12:34 ET
|
Minovia Therapeutics
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved...
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET
|
Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Automated and Closed Cell Therapy Market Research 2024-2029 Featuring Leading Players - Danaher, Thermo Fischer Scientific, Lonza, and Sartorius
September 24, 2024 09:22 ET
|
Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the global market...
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
September 24, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
Cell & Gene Therapy Manufacturing Services Market Size Worth US$ 70.7 Billion by 2032, Amid Rising Clinical Trials | Research by SNS Insider
September 17, 2024 08:45 ET
|
SNS Insider pvt ltd
Pune, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cell & Gene Therapy Manufacturing Services Market Analysis: “The Cell & Gene Therapy Manufacturing Services Market is experiencing rapid growth,...